MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Auricular Acupuncture Stimulation for Chronic Pain

Not Applicable

Active, not recruiting

Conditions: Low Back Pain

Interventions: Other: Stimulation at Location 2
Other: Stimulation at Location 1

First Posted Date: 2019-05-22

Last Posted Date: 2023-03-09

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 70

Registration Number: NCT03959111

Locations: 🇺🇸
Massachusetts General Hospital, Charlestown, Massachusetts, United States

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Ipatasertib
Drug: Aromatase Inhibitor
Drug: Fulvestrant
Drug: Palbociclib

First Posted Date: 2019-05-22

Last Posted Date: 2024-04-16

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 77

Registration Number: NCT03959891

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Inflammatory Bowel Disease Tracker (IBD Tracker)

Withdrawn

Conditions: Crohn Disease
Inflammatory Bowel Diseases
Ulcerative Colitis

Interventions: Device: Fitbit Charge 3

First Posted Date: 2019-05-17

Last Posted Date: 2020-04-28

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT03953794

Version 2 of the Smoking Cessation Smartphone App "Smiling Instead of Smoking" (SiS)

Not Applicable

Completed

Conditions: Smoking, Tobacco
Smoking Cessation

Interventions: Behavioral: Smiling Instead of Smoking (SiS) App Version 2

First Posted Date: 2019-05-15

Last Posted Date: 2022-07-26

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 100

Registration Number: NCT03951766

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients

Phase 1

Active, not recruiting

Conditions: Triple Negative Breast Cancer
Residual Disease

Interventions: Drug: Niraparib
Radiation: Radiation Therapy

First Posted Date: 2019-05-10

Last Posted Date: 2025-02-27

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 20

Registration Number: NCT03945721

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts, United States

VE416 for Treatment of Food Allergy

Phase 1

Recruiting

Conditions: Peanut Allergy

Interventions: Combination Product: Vancomycin plus VE416 before PNOIT
Combination Product: Vancomycin plus VE416 with PNOIT
Combination Product: Placebo plus placebo with PNOIT
Combination Product: Placebo plus VE416 with PNOIT

First Posted Date: 2019-05-03

Last Posted Date: 2023-10-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 60

Registration Number: NCT03936998

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Phase 1

Recruiting

Conditions: Neurological Cancer

Interventions: Drug: ASTX727

First Posted Date: 2019-04-22

Last Posted Date: 2024-03-29

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 18

Registration Number: NCT03922555

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Phase 2

Terminated

Conditions: Follicular Lymphoma
Follicular Lymphoma, Grade 1
Follicular Lymphoma Grade 2
Follicular Lymphoma Grade IIIa
Marginal Zone Lymphoma
Marginal Zone B Cell Lymphoma
Lymphoma

Interventions: Drug: Umbralisib
Drug: Rituximab

First Posted Date: 2019-04-18

Last Posted Date: 2024-05-08

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 18

Registration Number: NCT03919175

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States

A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth

Phase 4

Completed

Conditions: Mood Disorders
Alternative Treatment
Mood Disturbance
Natural Supplements

Interventions: Drug: Open-label Treatment with Omega-3 Fatty Acids + Inositol
Drug: Open-label Treatment with N-acetylcysteine

First Posted Date: 2019-04-11

Last Posted Date: 2025-05-07

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 37

Registration Number: NCT03911414

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Arthroscopic Labral Repair Versus Physical Therapy for Tears of the Acetabular Labrum

Not Applicable

Active, not recruiting

Conditions: Hip Arthroscopy
Femoro Acetabular Impingement
Physical Therapy
Osteoarthritis, Hip
Acetabular Labrum Tear

Interventions: Procedure: Hip Arthroscopy Surgery with Acetabular Labral Repair (SPT group)
Procedure: Physical Therapy Focused on the Hip and Hemi-pelvis (PT group)

First Posted Date: 2019-04-09

Last Posted Date: 2024-04-09

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 110

Registration Number: NCT03909178

Locations: 🇺🇸
MGH, Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy